Skip to content

Gross margin at other companies

United Therapeutics logo
United TherapeuticsUTHR
86.6%-2.4pp
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
98.4%-0.2pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
95.1%-0.2pp
TG Therapeutics logo
TG TherapeuticsTGTX
83.1%-4.4pp
Alkermes logo
AlkermesALKS
86.6%+2.2pp
ALN
Alnylam PharmaceuticalsALNY
81%-5.3pp

Other financials

Income statement

See full
Revenue$132.9M+4,158%
Gross profit$1.6M+6.5%
Operating income$61.5M+274%
Net income$52.9M+238%
EPS (diluted)$0.52+216%

Balance sheet

See full
Cash & equivalents$222.8M+31.2%
Total debt$7.0M+1.5%
Total equity$108.6M+118%
Total assets$401.5M+76.6%

Cash flow

See full
Operating cash flow$53.0M+273%
CapEx$2.8M+758%
Free cash flow$50.2M+262%

Valuation

See full
Market cap$6.32B+164%
Enterprise value$6.1B+184%
P/S21.9×-147×

Profitability

See full
Operating margin-155%-68.1pp
Net margin-176.2%-76.4pp
FCF margin-150.7%-64.4pp

Returns & leverage

See full
Return on equity-181%+57.4pp
Debt / equity0.1×-0.1×
Current ratio2.2×-0.7×

Where this comes from

Calculated from Liquidia Corporation’s reported figures.

Based on trailing twelve months.

The official record: Liquidia Corporation’s 10-Q, filed May 8, 2025, on SEC EDGAR. View the filing →

Ask your AI about Liquidia Corporation's gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Liquidia Corporation's gross margin?
Liquidia Corporation (LQDA) reported gross margin of 58.1% in Q1 2025.
How has Liquidia Corporation's gross margin changed year-over-year?
Liquidia Corporation's gross margin decreased by 24.4% year-over-year, from 76.8% to 58.1%.
What is the long-term trend for Liquidia Corporation's gross margin?
Over 4 years (2020 to 2024), Liquidia Corporation's gross margin has grown at a -3.9% compound annual growth rate (CAGR), from 67.9% to 58%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.